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Rationale Screening has been found to reduce breast cancer mortality at a population level in
Australia, but these studies did not address local settings where numbers of deaths would gener-
ally have been too low for evaluation. Clinicians, administrators, and consumer groups are also
interested in local service outcomes. We therefore use more common prognostic and treatment
measures and survivals to gain evidence of screening effects among patients attending 4 local
hospitals for treatment.
Aims and objectives To compare prognostic, treatment, and survival measures by screening
history to determine whether expected screening effects are occurring.
Methods Employing routine clinical registry and linked screening data to investigate associa-
tions of screening history with these measures, using unadjusted and adjusted analyses.
Results Screened women had a 10‐year survival from breast cancer of 92%, compared with
78% for unscreened women; and 79% of screened surgical cases had breast conserving surgery
compared with 64% in unscreened women. Unadjusted analyses indicated that recently screened
cases had earlier tumor node metastasis stages, smaller diameters, less nodal involvement, better
tumor differentiation, more oestrogen and progesterone receptor positive lesions, more hor-
mone therapy, and less chemotherapy. Radiotherapy tended to be more common in screening
participants. More frequent use of adjunctive radiotherapy applied when breast conserving sur-
gery was used.
Conclusions Results confirm the screening effects expected from the scientific literature and
demonstrate the value of opportunistic use of available registry and linked screening data for
indicating to local health administrations, practitioners, and consumers whether local screening
services are having the effects expected.
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Roll‐out of population‐based breast cancer screening com-
menced in Australia in 1991, directed principally at 50‐ to 69‐
year‐old women until 2013‐2014 when this age range was
extended to 50‐74 years.1,2 Four separate evaluation studies
indicated breast cancer mortality reductions in screening partici-
pants in the 34% to 52% range.3–7 Estimates of overdiagnosis
varied widely with jurisdiction and methodology.8,9
Less attention has been given in Australia to quantifying
screening effects in local operational settings where numbers of
deaths are often too small for evaluation purposes. Use of more
prevalent prognostic characteristics, patterns of care, and post‐diag-
nostic survivals may be more applicable as performance indicators
of screening effect in these settings.
Lead‐time effects of screening are well known and post‐diag-
nostic survivals unadjusted for lead time should not be used to
evaluate mortality effects of screening.10,11 However, post‐diagnos-
tic survival data are of great interest and relevance to clinicians and
patients when considering prognosis.12 Also, if screening is working
as intended, both lead‐time effects and actual mortality reductions
would be expected to increase measured post‐diagnostic sur-
vivals,10,11 which can therefore be used as an indicator of whether
local screening services are working as intended.
Prognostic data for early invasive breast cancers reported by
surgeons in the BreastSurgANZ QUALITY Audit indicated that
BreastScreen referrals had smaller tumor diameters than symp-
tomatic cases (54% ≤15 mm compared with 28%), fewer high‐
grade cancers (20% compared with 37%), fewer node positive
cancers (28% compared with 44%), and a higher proportion of
hormone receptor positive tumors (ie, 87% compared with 78%
estrogen receptor positive; 73% compared with 66% progester-
one receptor positive).13 Audit data also indicated that the pro-
portion having breast‐conserving surgery was higher for
BreastScreen referrals (74% compared with 56% for symptomatic
referrals).13 Surgeons reported a higher proportion of referrals of
BreastScreen cases for first‐round adjuvant treatments by radio-
therapy (78% compared with 68%) and hormone treatment byaromatase inhibitor (49% compared with 37%), but fewer referrals
for chemotherapy (37% compared with 55%) and ovarian ablation
(1% compared with 3%).
Other studies show similar associations between breast
screening and smaller cancer size, negative nodal status, lower
tumor grade, hormone receptor positive cancers (estrogen and/
or progesterone receptors), non‐ductal histology types, surgical
treatment by breast conservation, and higher post‐diagnostic
survivals.14–22 Opportunity therefore presents to use these char-
acteristics as indicators of screening effect in individual opera-
tional settings.
In this study we compare the prognostic profiles, treatments,
and post‐diagnostic survival outcomes of 2039 invasive female
breast cancers diagnosed in 50‐ to 69‐year‐olds in 1997‐2010
who were treated at 4 major public hospitals in South Australia
(1 of 8 Australian states/territories), according to whether cases
had participated in BreastScreen and according to duration since
last BreastScreen participation.23,24 The purpose was to determine
whether BreastScreen was delivering the outcomes expected in
these local operational settings.
Data from these hospitals are not population‐based but cov-
ered about half the South Australian female breast cancers diag-
nosed in the principal screening age range of 50‐69 years during
the study period. The study period of 1997‐2010 followed initial
roll‐out of the BreastScreen program that reached a plateau in
population coverage during the mid‐1990s. The study therefore
investigates effects of a fully developed screening program.
Although not population‐based, the characteristics of patients
at these major hospitals and their screening outcomes are of
direct interest to clinicians and patients at these hospitals.23,24
In addition, the data can be used as performance indicators by
health administrations to interpret screening and other local
health‐system effects.12,23,24
We hypothesized, based on BreastSurgANZ Quality Audit
data and the international evidence,13–22 that screen‐detected
and other recently screened cases in this study would have: (1)
higher post‐diagnostic survivals; (2) earlier stage characteristics
(smaller diameters, less nodal involvement, and lower tumor
RODER ET AL. 3node metastasis [TNM] stage), less high‐grade histology, and
more estrogen and progesterone receptor positive lesions; and
(3) more conservative breast surgery, more radiotherapy, and
more hormone therapy, but less chemotherapy. If this pattern
were found, we decided a priori that these data, alongside the
previously reported breast cancer mortality reductions,3–6 would
indicate that breast screening was delivering the outcomes
expected in these local operational settings.
Because source data came primarily from hospitals, adjuvant
therapies commencing post‐discharge would often have been
excluded.24 Emphasis has therefore been placed on assessing com-
parative rather than absolute exposures to adjuvant treatments
according to BreastScreen participation.242 | METHODS
Operations of the South Australian Clinical Cancer Registry
(SACCR) have been described previously in SA Cancer Registry
reports.25 Ethical approval for the study was provided by the
South Australian Human Research Ethics Committee. The SACCR
is authorized under Section 64D of the South Australian Health
Care Act (2008) to support quality assurance of service activ-
ity.26 Patient consent is not legally required to use the data for
quality assurance or research, so long as reported data are non‐
identifiable.26
Data linkage of extracted SACCR and BreastScreen South
Australia data was used to identify histories of BreastScreen par-
ticipation among women aged 50‐69 years at invasive breast can-
cer diagnosis.24 This was classified as no participation or
participation last occurring <6 months, 6‐24 months, or 25+
months prior to breast cancer diagnosis. Probabilistic data linkage
was used based on full names and dates of birth as linking vari-
ables, with additional guidance from residential address, with a
false positive rate of about 3 per 1000.24
Postcode of residence was used to indicate socioeconomic
quartile, using the SEIFA Index of Relative Socioeconomic Dis-
advantage; geographic remoteness (classified as metropolitan,
regional, and remote); and locality by Local Health Network
(central, southern, northern, and country) and former Medicare
Local of residence (northern, central, southern, country south,
and country north).27,28 The term “country” referred to areas
outside the metropolitan capital of South Australia, which have
poorer access to tertiary services and which were subclassified
by Medicare Local area (as south or north) according to official
government boundaries.28 These variables were chosen to
investigate and adjust for the sociodemographic impact of
screening.
Person characteristics were analyzed, depending on their dis-
tribution, as age at diagnosis (four 5‐year ordinal categories);
SEIFA socioeconomic disadvantage (4 ordinal categories), geo-
graphic remoteness (3 ordinal categories), Local Health Network
(4 nominal categories), and Medicare Local (5 nominal catego-
ries). Tumor characteristics, including histology, TNM (UICC 7thRevision) stage, diameter, nodal status, differentiation, and estro-
gen and progesterone receptor status were classified as shown
in Table 1.24,25
Primary site was coded according to the International Classifi-
cation of Disease (version 3) (ICD‐O‐3), or corresponding ICD‐9
codes for earlier years, and histology type using ICD‐O‐3 or Sys-
tematized Nomenclature of Medicine II codes for earlier years.24,25
Tumor diameters, nodal status, and hormone receptor status were
extracted from pathology reports.24,25 First‐round treatments were
recorded as including surgery—specifying type as mastectomy or
breast‐conserving surgery—and according to whether radiotherapy
and/or systemic therapies were provided.
Death data were extracted from the South Australian popu-
lation‐based cancer registry, which used official death files, and
for deaths occurring outside of South Australia, the National
Death Index at the Australian Institute of Health and Welfare
as data sources, although correcting underlying causes‐of‐death
when clinical data available to the registry indicated this to be
appropriate.24,25 The extent of loss to follow‐up of deaths has
been checked through active tracing and found to be minimal
and to have little effect on calculated survivals.25,29
Disease‐specific survivals were calculated using Kaplan‐
Meier product limit estimates, with censoring of live cases on
December 31, 2012.30,31 This method was preferred to relative
survival because risks of deaths from competing causes could
not be assumed to be equivalent to population norms (an under-
lying assumption for relative survival) because of the referral of
high‐risk cases (including those with high levels of comorbidity)
to the referral centers covered by the SACCR.25
Population‐based data show disease‐specific survival, based
on South Australian registry coding, to be a good proxy for rela-
tive survival for female breast cancer. For example, a 1977‐2003
study gave cohort relative survivals of 80% at 5 years and 69%
at 10 years following diagnosis that were virtually identical to
corresponding disease‐specific survivals of 80% and 70%,
respectively.32 This validation is important as cause‐specific sur-
vivals are known to be vulnerable to variations in cause‐of‐death
coding.33
Cox proportional hazards regression analyses were used to
examine differences in disease‐specific survival by BreastScreen
participation, and person and tumor characteristic. This was under-
taken both for single predictors and in multivariable analyses, using
the same follow‐up period and censoring rules as for the Kaplan‐
Meier analyses.30,31 Two sets of multivariable analyses were
performed, the first incorporating TNM stage and the second,
tumor diameter and nodal status instead of TNM stage. As results
were very similar, only outputs from models using TNM stage are
presented in this report.
Assumptions underlying the Cox regression analyses, includ-
ing proportionality and lack of colinearity, were tested and found
to be met. When competing risk regression was substituted for
disease‐specific Cox proportional hazards regression, similar
results applied (data not shown).30,31
First‐round treatments were analyzed by BreastScreen expo-
sure, person, and tumor characteristic using the Pearson chi‐square
TABLE 1 Female breast cancer characteristics by duration from last breast screen to time of diagnosis, 1997‐2010—recorded by major public
hospitals in South Australiaa
Characteristic
No Past Screen
(%) (n = 635)
Duration
<6 mo (%) (n = 977)
Duration
6‐24 mo (%) (n = 255)
Duration
25+ mo (%) (n = 172) P Value
Histology:
Ductal 81.7 (n = 519) 76.3 (n = 745) 74.1 (n = 189) 78.5 (n = 135) X2
Lobular 8.7 (n = 55) 11.8 (n = 115) 14.1 (n = 36) 14.0 (n = 24) (df = 6)
Other 9.6 (n = 61) 12.0 (n = 117) 11.8 (n = 30) 7.6 (n = 13) P = .044
Total 100 (n = 635) 100 (n = 977) 100 (n = 255) 100 (n = 172)
TNM stage:b
I 31.3 (n = 190) 62.2 (n = 599) 32.9 (n = 82) 32.1 (n = 54) KWp < 0.001
IIA 28.8 (n = 175) 24.5 (n = 236) 33.7 (n = 84) 25.6% (n = 43)
IIB/IIUK 20.1 (n = 122) 8.9 (n = 86) 18.5 (n = 46) 24.4 (n = 41)
IIIA 5.3 (n = 32) 2.2 (n = 21) 7.6 (n = 19) 6.0 (n = 10)
IIIB/IIIUK 3.1 (n = 19) 0.4 (n = 4) 2.4 (n = 6) 1.8 (n = 3)
IV 11.4 (n = 69) 1.8 (n = 17) 4.8 (n = 12) 10.1 (n = 17)
Total 100 (n = 607) 100 (n = 963) 100 (n = 249) 100 (n = 168)
Diameter (mm):b
<10 11.6 (n = 67) 26.1 (n = 246) 16.4 (n = 39) 11.5 (n = 18) KWp < 0.001
10‐14 14.8 (n = 86) 28.2 (n = 266) 13.0 (n = 31) 12.8 (n = 20)
15‐19 16.4 (n = 95) 18.1 (n = 171) 16.0 (n = 38) 13.5 (n = 21)
20‐29 22.6 (n = 131) 16.8 (n = 158) 30.7 (n = 73) 35.3 (n = 55)
30‐39 15.2 (n = 88) 5.5 (n = 52) 10.1 (n = 24) 11.5 (n = 18)
40+ 19.5 (n = 113) 5.3 (n = 50) 13.9 (n = 33) 15.4 (n = 24)
Total 100 (n = 580) 100 (n = 943) 100 (n = 238) 100 (n = 156)
Nodal status:b
Negative 46.4 (n = 286) 71.0 (n = 685) 44.6 (n = 112) 45.6 (n = 77) X2
Positive 53.6 (n = 330) 29.0 (n = 280) 55.4 (n = 139 54.4 (n = 92) (df = 3)
Total 100 (n = 616) 100 (n = 965) 100 (n = 251) 100 (n = 169) P < .001
Differentiation:b
Well 21.6 (n = 125) 40.8 (n = 376) 20.5 (n = 49) 22.5 (n = 36) KWp = 0.001
Moderate 40.0 (n = 231) 42.4 (n = 391) 39.7 (n = 95) 41.3 (n = 66)
Poor/undifferentiated 38.4 (n = 222) 16.8 (n = 155) 39.7 (n = 95) 36.3 (n = 58)
Total 100 (n = 578) 100 (n = 922) 100 (n = 239) 100 (n = 160)
Estrogen receptor:
Negative 24.9 (n = 158) 14.1 (n = 138) 27.8 (n = 71) 20.3 (n = 35) X2
Positive 75.1 (n = 477) 85.9 (n = 839) 72.2 (n = 184) 79.7 (n = 137) (df = 3)
Total 100 (n = 635) 100 (n = 977) 100 (n = 255) 100 (n = 172) P < .001
Progesterone receptor:
Negative 27.2 (n = 173) 18.3 (n = 179) 30.6 (n = 78) 23.3 (n = 40) X2
Positive 72.8 (n = 462) 81.7 (n = 798) 69.4 (n = 177) 76.7 (n = 132) (df = 3)
Total 100 (n = 635) 100 (n = 977) 100 (n = 255) 100 (n = 172) P < .001
TNM, tumor node metastasis.
aData from South Australian Clinical Cancer Registry (see text).
bMissing values—all cases: TNM (n = 52), diameter (n = 122), nodal status (n = 38), differentiation (n = 140).
‐ No past screen: TNM (n = 28), diameter (n = 55), nodal status (n = 19), differentiation (n = 57).
‐ Duration <6 mo: TNM (n = 14), diameter (n = 34), nodal status (n = 12), differentiation (n = 55).
‐ Duration 6 to 24 mo: TNM (n = 6), diameter (n = 17), nodal status (n = 4), differentiation (n = 16).
‐ Duration 25+ mo: TNM (n = 4), diameter (n = 16), nodal status (n = 3), differentiation (n = 12).
4 RODER ET AL.or Kruskal‐Wallis analysis of variance, depending on whether vari-
ables were distributed on binary, nominal, or ordinal scales.30,31
Univariate and multiple logistic regression analyses were also
used.30,31 Multivariable analyses were undertaken to check forconfounding, effect modification, and clustering by treatment cen-
ter, but did not show statistically significant effects, and so the
data presented here are from conventional analyses unadjusted
for such effects.30
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3.1 | Descriptive characteristics
Residential remoteness, socioeconomic status, Local Health Network,
and Medicare Local did not differ by BreastScreen participation in
bivariable analyses (P values ≥ .077). Age did vary (P < .001), with
BreastScreen participants more likely to be aged 60+ years (56.5% vs
45.2%). The proportion aged 60+ years was also higher among
BreastScreen participants with the shortest duration since last screen
(ie, 58.3% for <6 months vs 52.2% for 6+ months) (P = .033).
Table 1 shows differences by BreastScreen participation/duration
since last screen, according to: (1) histology type (P = .044)—partici-
pants having more lobular and other non‐ductal cancers; (2) TNM
stage (P < .001)—participants having earlier stages; (3) diameters
(P < .001)—participants having smaller cancers; (4) nodal status
(P < .001)—fewer participants having positive nodes; (5) differentiation
(P = .001)—participants having better differentiated lesions; and (6)
estrogen receptor status (P < .001) and progesterone receptor status
(P < .001)—participants more likely to have a positive estrogen and
progesterone receptor status. Apart from histology type (P = .334),
BreastScreen participants last screened within 6 months were more
likely to show these features than participants screened less recently
(P < .001 for each characteristic).3.2 | Survivals
Five‐year survivals were highest at 95.7% for BreastScreen partici-
pants last screened within 6 months of diagnosis and lowest atTABLE 2 Disease‐specific survivals from female breast cancer, diagnosed i









No past screen (n = 635) 95.8 92.1 84
Duration <6 m (n = 977) 99.6 98.7 95
Duration 6‐24 m (n = 255) 98.4 95.3 89
Duration 25+ m (n = 172) 95.4 92.4 86
Any duration (n = 1404) 98.9 97.3 93
aKaplan‐Meier disease‐specific survival; Cox proportional hazards ratios (95% c
bAdjusted for histology type, grade, TNM stage, estrogen receptor status, prog
socioeconomic status, remoteness, Local Health Network, and Medicare Local
TABLE 3 Percentage of female breast cancer surgical cases diagnosed in 1
duration from last breast screen to time of diagnosis—recorded by major p
Duration From Last Breast Screen % Having BCS
Odds
No past screen (n = 573) 64.2
Duration <6 mo (n = 888) 78.6
Duration 6‐24 mo (n = 228) 71.1
Duration 25+ mo (n = 157) 67.5
Any duration screen (n = 1273) 75.9
BCS, breast‐conserving surgery.
aLogistic regression (see text); odds ratios (95% confidence limits).
bMultiple logistic regression, adjusted for histology type, grade, TNM stage, estr
diagnosis, and residential socioeconomic status, remoteness, Local Health Net84.3% for those without a BreastScreen history (Table 2). Ten‐year
survivals showed a similar pattern (Table 2). Similarly, unadjusted haz-
ards ratios (HRs) were lowest for those last screened within 6 months
(HR 0.30, 95% confidence limits: 0.22, 0.41) when compared with the
never screened. A reduced unadjusted HR also applied for those last
screened within 6‐24 months of diagnosis (HR 0.67 (0.46, 0.97)), but
there was little evidence of a reduction for those screened 25 or more
months before diagnosis (Table 2). Overall, BreastScreen participants
had a reduced unadjusted HR of 0.43 (0.34, 0.55).
Unadjusted HRs were higher for more advanced TNM stages
(P < .001) (and larger cancers [P < .001] and node positive cases
[P < .001]), more poorly differentiated tumors (P < .001), and estrogen
receptor negative (P < .001) and progesterone receptor negative
(P < .001) tumors. Outcomes also varied by histology type (P = .005),
with lower HRs suggested for non‐ductal cancers. By comparison, little
evidence of survival differences presented by age at diagnosis or resi-
dential location classified by socioeconomic status, remoteness, or
local health service administration (Local Health Network/Medicare
Local), or diagnostic period.
After adjusting for these variables, reductions in HRs for
BreastScreen participants were no longer statistically significant
(P ≥ .116) (Table 2).3.3 | Treatments
Surgery—Breast surgery treatment was recorded for 93.5% of breast
cancers and surgery type for 90.5% of these cases. The percentage









.3 78.0 1.00 1.00
.7 92.1 0.30 (0.22, 0.41) 0.77 (0.56, 1.07)
.2 84.6 0.67 (0.46, 0.97) 0.82 (0.55, 1.21)
.3 81.5 0.87 (0.58, 1.31) 0.90 (0.59, 1.37)
.4 89.5 0.43 (0.34, 0.55) 0.81 (0.63, 1.05)
onfidence limits); date of censoring of live cases—December 31, 2012.
esterone receptor status, diagnostic year, age at diagnosis, and residential
(see text).
997‐2010 who were treated by BCS rather than mastectomy, by
ublic hospitals in South Australiaa
Ratio—BCS vs Mastectomy
(Unadjusted)
Odds Ratio—BCS vs Mastectomy
(Adjustedb)
1.00 1.00
2.05 (1.62, 2.59) 1.47 (1.13, 1.91)
1.37 (0.98, 1.91) 1.54 (1.07, 2.21)
1.16 (0.80, 1.68) 1.21 (0.81, 1.82)
1.76 (1.48, 2.08) 1.44 (1.13, 1.82)
ogen receptor status, progesterone receptor status, diagnostic year, age at
work, and Medicare Local (see text).
TABLE 4 Percentage of female breast cancer cases diagnosed in 1997‐2010 who were treated by radiotherapy and/or systemic therapies as part

































89.2 1.00 1.00 70.7 1.00 1.00
Duration <6 mo
(n = 964)
87.7 0.86 (0.62, 1.20) 1.13 (0.81, 1.59) 73.8 1.16 (0.92, 1.46) 1.16 (0.91, 1.48)
Duration 6‐24 mo
(n = 249)
82.7 0.58 (0.37, 0.89) 1.50 (0.89, 2.53) 79.1 1.56 (1.08, 2.24) 1.54 (1.08, 2.21)
Duration 25+ mo
(n = 168)
91.1 1.24 (0.67, 2.33) 1.09 (0.62, 1.93) 72.0 1.07 (0.72, 1.59) 1.04 (0.71, 1.53)
Any duration
(n = 1381)
87.2 0.82 (0.60, 1.12) 1.19 (0.87, 1.62) 74.5 1.21 (0.97, 1.50) 1.21 (0.97, 1.51)
(Continues)
6 RODER ET AL.highest at 78.6% for those screened within 6 months of diagnosis and
lowest at 64.2% for those never screened (Table 3). Compared with
those never screened, logistic regression gave the highest unadjusted
odds ratio (OR with 95% confidence limits) for breast‐conserving sur-
gery of 2.05 (1.62, 2.59) for those screened within 6 months and
1.76 (1.48, 2.08) for those ever screened (irrespective of duration
between screening and diagnosis).
Unadjusted ORs for breast‐conserving surgery were lower for
higher stages (P < .001) (including larger tumors [P < .001] and node
positive cases [P < .001]), poorer differentiated cancers (P < .001),
and lobular histology (P < .001), and higher for more recent diagnostic
years (P = .019). Variations also applied by residential Local Health
Network (P = .001) and Medicare Local (P = .008), with lower odds of
breast‐conserving surgery tending to apply in central localities. Little
variation in surgery type was suggested by age at diagnosis, estrogen
and progesterone receptor status, and residential location classified
by socioeconomic status or remoteness.
After adjusting for these tumor and demographic variables, ORs
for breast‐conserving surgery were still elevated at 1.47 (1.13, 1.91)
for those screened within 6 months and 1.44 (1.13, 1.82) for those
ever screened (Table 3). An elevated adjusted OR of 1.54 (1.07, 2.21)
also was suggested for cases who had been screened within 6‐
24 months of diagnosis compared with those never screened.
Radiotherapy and/or systemic therapy—Details of these therapies were
recorded for 98.2% of breast cases, with 87.8% of them recording 1
or more therapies. Little variation was suggested by BreastScreen
exposure and duration since last screen in unadjusted analysis, except
that use of ≥1 of these therapies tended to be lower in cases last
screened within 6‐24 months of diagnosis when compared with those
without a past screen (OR of 0.58 (0.37, 0.89)) (Table 4). Similarly, little
variation was suggested in adjusted analyses (Table 4)—even though
unadjusted ORs for 1 or more of these therapies were elevated for
more advanced TNM (P < .001) (including for larger cancers
[P < .001] and node positive cases [P < .001]) and poorer differentia-
tion (P = .036). The odds of radiotherapy and/or systemic therapy were
lower, but not significantly so, in unadjusted analyses of cases who had
obtained breast‐conserving surgery rather than a mastectomy—an OR
of 0.78 (0.57, 1.07).Radiotherapy—Of cases with radiotherapy details available, 73.3%
received this treatment. The percentage was highest at 79.1% for
those last screened within 6‐24 months of diagnosis and lowest at
70.7% for those never screened. Compared with those never screened,
the unadjusted OR for radiotherapy was 1.56 (1.08, 2.24) for those
screened within 6‐24 months of diagnosis (Table 4).
Unadjusted ORs logistic regression indicated a difference in radio-
therapy by age (P = .048), with a relatively low radiotherapy exposure
for 65‐ to 69‐year‐olds. Little difference was evident by other demo-
graphic and cancer characteristics or diagnostic epoch.
After adjusting for tumor and demographic variables, the OR for
radiotherapy among those screened within 6‐24 months remained ele-
vated at 1.54 (1.08, 2.21) when compared with the never screened
(Table 4). In a separate unadjusted analysis, the odds of radiotherapy
were higher among cases who obtained breast‐conserving surgery
than among mastectomy cases—an OR of 2.86 (2.29, 3.58).
Chemotherapy—Of cases with chemotherapy details available, 32.7%
received this treatment. The percentage was lowest at 19.4% for those
last screened within 6 months of diagnosis and highest at 53.0% for
those last screened 6‐24 months earlier (Table 4). Compared with
those never screened, unadjusted OR for chemotherapy was lowest
at 0.32 (0.26, 0.40) for those last screened within 6 months. This
compared with 1.45 (1.08, 1.94) for those last screened within 6‐
24 months, and 0.51 (0.42, 0.62) for those ever screened, irrespective
of duration before diagnosis.
Unadjusted ORs for chemotherapy were lower for older groups
(P < .001), less advanced TNM stage (P < .001) (including smaller can-
cers [P < .001] and node negative tumors [P < .001]), better differenti-
ation (P < .001), non‐ductal cancers (P < .001), and estrogen receptor
positive (P < .001) and progesterone positive (P = .003) tumors. Higher
odds of chemotherapy were suggested for residents of the Central
Local Health Network (P = .023) and Central Medicare Local
(P = .032). Chemotherapy was more likely in the 2004‐2010 than
1997‐2003 diagnostic epoch (P = .046). Little variation applied by res-
idential socioeconomic status and remoteness.
After adjusting for tumor and demographic variables, and compared
with those never screened, the OR for chemotherapy among those last






























43.4 1.00 1.00 49.2 1.00 1.00
Duration <6 mo
(n = 964)
19.4 0.32 (0.26, 0.40) 0.81 (0.60, 1.09) 54.5 1.24 (1.02, 1.53) 1.09 (0.87, 1.38)
Duration 6‐24 mo
(n = 249)
53.0 1.45 (1.08, 1.94) 1.78 (1.21, 2.61) 42.6 0.76 (0.57, 1.03) 0.79 (0.57, 1.09)
Duration 25+ mo
(n = 168)
38.7 0.82 (0.58, 1.16) 0.73 (0.46, 1.15) 49.4 1.00 (0.72, 1.40) 0.90 (0.62, 1.30)
Any duration
(n = 1381)
27.8 0.51 (0.42, 0.62) 0.97 (0.75, 1.26) 51.7 1.11 (0.92, 1.34) 0.99 (0.80, 1.23)
aLogistic regression (see text); odds ratios (95% confidence limits).
bMultiple logistic regression, adjusted for histology type, grade, TNM stage, estrogen receptor status, progesterone receptor status, diagnostic year, age at
diagnosis, and residential socioeconomic status, remoteness, Local Health Network, and Medicare Local (see text).
RODER ET AL. 7(Table 4). In an unadjusted analysis, chemotherapy was found to be less
common among cases treated by breast conservative surgery thanmas-
tectomy irrespective of screening history—an OR of 0.39 (0.32, 0.49).
Hormone therapy—Of women with hormone therapy data available,
50.9% were recorded to have received this treatment. The percentage
was highest at 54.5% when screening was undertaken within 6 months
of diagnosis (Table 4). Compared with those never screened, the
unadjusted OR for hormone therapy was 1.24 (1.02, 1.53) for these
recently screened women.
Unadjusted logistic ORs for hormone therapy varied by age
(P = .038) (tending to be higher for 65‐ to 69‐year‐olds) and were
higher for lobular lesions (P = .005), better differentiated lesions
(P < .001), and estrogen receptor positive (P < .001) and progesterone
receptor positive lesions (P < .001). There was also a variation by resi-
dential Local Health Network (P < .001) and Medicare Local (P < .001),
with higher ORs tending to apply for central than other localities. Little
variation in ORs was evident by residential socioeconomic status,
remoteness or tumor stage, size, nodal status, or diagnostic epoch.
After adjusting for tumor and demographic variables, little varia-
tion in ORs of hormone therapy was observed by screening history
(Table 4). An unadjusted analysis indicated that hormone therapy
was less common among cases treated by breast conservative
surgery than mastectomy, irrespective of screening history—an OR
of 0.65 (0.52, 0.80).4 | DISCUSSION
We have been opportunistic in using readily available clinical registry
and linked screening data to evaluate local screening effects. Results
confirm a priori hypotheses, in that women screened within 6 months
of diagnosis had a 10‐year survival from breast cancer of 92% com-
pared with 78% for unscreened women.10 Of surgical cases diagnosed
within 6 months of screening, 79% had breast‐conserving surgery,
which was significantly higher than the 64% having breast‐conserving
surgery among unscreened women.Our unadjusted results are consistent with previous study results,
indicating that recently screened cases had higher post‐diagnostic sur-
vivals, earlier TNM stage, smaller diameters, less nodal involvement,
better tumor differentiation, more estrogen and progesterone receptor
positive lesions, more breast‐conserving surgery, and more hormone
therapy, but less chemotherapy.13–23
It is likely that adjusted analyses did not show the differences in
survivals, chemotherapy, and hormone therapy seen in unadjusted
analyses, largely because of adjustment for the means whereby
screening was having an effect (eg, through achieving earlier stages,
smaller tumors, and fewer node positive tumors). By comparison, the
retention in adjusted analyses of evidence for greater use of adjuvant
radiotherapy among screened cases, particularly those last screened
within 6‐24 months of last diagnosis, may reflect greater use of
breast‐conserving surgery in these cases and recommendations that
adjuvant radiotherapy be given for cases so treated.34
The higher odds of chemotherapy 6‐24 months post screen were
unexpected and warrant further investigation. Although alternative
explanations may apply, potentially it could reflect the timing of inter-
val cancers with aggressive characteristics or the progression of some
cases diagnosed earlier through screening who did not respond to
early care.
While increased breast‐conserving therapy would generally be
regarded as a screening benefit for improved body image and psycho-
logical outcomes, any side effects from exposure to radiotherapy
would need to be considered (eg, potential for cardio‐toxicity from
radiation to the left breast).35 By comparison, mastectomy cases were
more likely to receive chemotherapies and hormone therapies. To the
extent that these systemic therapies can have adverse effects—fatigue,
nausea, weight loss, mucositis, immunosuppression, and cardio‐toxic-
ities—the reduced need for these therapies in screened cases would
be regarded as a positive screening effect.36
The present results are consistent with international and earlier
Australian evidence of screening effects on prognosis, treatment, and
post‐diagnostic survivals rather than providing new scientific
insights.11–22,37 Their importance is demonstrating the feasibility of
8 RODER ET AL.using local clinical registry and linked screening data to produce indica-
tors of screening effects of local services along the diagnostic, treat-
ment, and post‐diagnostic pathway. This was so in this study despite
inconsistencies in data completeness, as in the tendency for higher
completeness of data for screened than unscreened cases (eg, com-
pleteness of 98.3% compared with 95.6% for TNM; 95.2% compared
with 91.3% for diameter; and 98.7% compared 97.0% for nodal status).
These results also add value by complementing Australian evi-
dence of mortality reductions from screening by indicating expected
screening effects in local operational settings.3–6 This is important evi-
dence for local health service evaluation.
Other results also have policy implications, such as little or no evi-
dence of benefit from screening less frequently than biennially, and
evidence of differences in care patterns by screening history. These
results could be used in cost‐effectiveness research.
A broader network of clinical registries would be desirable to
broaden the evidence base across other localities. The reach of the
network could also be extended through linkage to population‐based
cancer registries that collect TNM stage and other prognostic markers
(note: as facilitated by greater use of structured pathology reporting),
and linkage to treatment data (note: as extracted from hospital inpa-
tient files, radiotherapy records, and health insurance claims), and to
BreastScreen data.38 This would enable evaluation to be broadened
from a health institution to population‐based focus.
Uncertainties are commonly expressed about the quality of
administrative data from hospitals and other service agencies for ser-
vice evaluation.38,39 Data quality audits are needed to ensure data
are fit‐for‐purpose. Comparisons of findings from administrative data
with overlapping data from clinical registries, clinical audits, and case‐
note reviews can be useful for this purpose. Even with limited
attention to data quality improvement, it is noteworthy that hospital
inpatient and other administrative data have shown high face‐value
validity in a number of studies.39
The roles of specialized clinical registries and linked administrative
data should be complementary. Clinical registries can provide “drill‐
down” data of high quality that are designed to meet the clinical mon-
itoring and research needs of their catchment institutions, whereas
linked administrative data can provide system‐wide data (albeit thin-
ner) for gaining a broader population‐wide perspective.38,39
Australia now has well‐defined data linkage protocols for pro-
ducing non‐identifiable databases for service monitoring and
research.38–40 Most jurisdictions, including the Commonwealth, have
access to data linkage facilities, and legal and ethically approved path-
ways exist for data linkage. With recent increases in data access,
opportunities have increased to include health insurance claims data
(Medical Benefits and Pharmaceutical Benefits data) in non‐identifiable
linked databases and for these data to be analyzed using remote access
for increased privacy protection.38 This will greatly increase the com-
pleteness and potential value of linked data sets for monitoring and
assessing patterns of care across operational settings, while minimizing
risk to privacy.
Cancer Australia is promoting the recording of TNM stage and
other prognostic characteristics on population registries.40 This would
be greatly facilitated by increased use of structured pathology
reporting developed through the Royal College of Pathologists ofAustralasia,41 especially if parallel development of electronic trans-
mission of these data as discrete data fields can occur, facilitating
automated entry into cancer registry systems.5 | CONCLUSIONS
• Clinical registry data indicate that breast screening in South
Australia has delivered expected changes in prognosis, treatment
patterns, and survival in patients attending 4 public hospitals. This
complements the evidence of mortality effects at a broader popu-
lation level.
• Greater use should be made of networks of clinical registries to
evaluate whether screening programs are having expected effects
in local settings. Complementary data from population‐based reg-
istries that record stage, linked to population‐wide administrative
data on cancer detection and treatment, should also be used for
this purpose.
• While lacking the clinical detail available in clinical registries, and
requiring prior data quality checks to ensure “fitness for purpose,”
linked administrative data have the advantage of providing popula-
tion‐wide evidence of local service performance.ACKNOWLEDGMENTS
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